UK authorizes Merck antiviral pill, 1st shown to treat COVID

Nov 3, 2021, 3:38 PM | Updated: Nov 4, 2021, 6:12 am
FILE - This undated image provided by Merck & Co. shows their new antiviral medication against COVI...

FILE - This undated image provided by Merck & Co. shows their new antiviral medication against COVID-19. Britain has granted a conditional authorization to Merck's coronavirus antiviral, the first pill shown to successfully treat COVID-19. It is the first country to OK the treatment, although it was not immediately clear how quickly the pill would be available. (Merck & Co. via AP, File)

(Merck & Co. via AP, File)

LONDON (AP) — Britain granted conditional authorization on Thursday to the first pill shown to successfully treat COVID-19 so far. It also is the first country to OK the treatment from drugmaker Merck, although it wasn’t immediately clear how quickly the pill would be available.

The pill was licensed for adults 18 and older who have tested positive for COVID-19 and have at least one risk factor for developing severe disease, such as obesity or heart disease. Patients with mild-to-moderate COVID-19 would take four pills of the drug, known molnupiravir, twice a day for five days.

An antiviral pill that reduces symptoms and speeds recovery could prove groundbreaking, easing caseloads on hospitals and helping to curb outbreaks in poorer countries with fragile health systems. It would also bolster the two-pronged approach to the pandemic: treatment, by way of medication, and prevention, primarily through vaccinations.

Molnupiravir is also pending review with regulators in the U.S., the European Union and elsewhere. The U.S. Food and Drug Administration announced last month it would convene a panel of independent experts to scrutinize the pill’s safety and effectiveness in late November.

Initial supplies will be limited. Merck has said it can produce 10 million treatment courses through the end of the year, but much of that supply has already been purchased by governments worldwide.

In October, U.K. officials announced they secured 480,000 courses of molnupiravir and expected thousands of vulnerable Britons to have access to the treatment this winter via a national study.

“Today is a historic day for our country, as the U.K. is now the first country in the world to approve an antiviral that can be taken at home for COVID-19,” British health secretary Sajid Javid said.

“We are working at pace across the government and with the NHS to set out plans to deploy molnupiravir to patients through a national study as soon as possible,” he said in a statement, referring to the U.K.’s National Health Service. Doctors said the treatment would be particularly significant for people who don’t respond well to vaccination.

Merck and partner Ridgeback Biotherapeutic have requested clearance for the drug with regulators around the world for adults with early cases of COVID-19 who are at risk for severe disease or hospitalization. That’s roughly the same group targeted for treatment with infused COVID-19 antibody drugs, the standard of care in many countries for patients who don’t yet require hospitalization.

Merck announced preliminary results in September showing its drug cut hospitalizations and deaths by half among patients with early COVID-19 symptoms. The results haven’t yet been peer reviewed or published in a scientific journal.

The company also didn’t disclose details on molnupiravir’s side effects, except to say that rates of those problems were similar between people who got the drug and those who received dummy pills.

The drug targets an enzyme the coronavirus uses to reproduce itself, inserting errors into its genetic code that slow its ability to spread and take over human cells. That genetic activity has led some independent experts to question whether the drug could potentially cause mutations leading to birth defects or tumors.

Britain’s Medicines and Healthcare products Regulatory Agency said molnupiravir’s ability to interact with DNA and cause mutations had been studied “extensively” and that it wasn’t found to pose a risk to humans.

“Studies in rats showed that (molnupiravir) may cause harmful effects to the unborn offspring, although this was at doses which were higher than those that will be given to humans, and these effects were not observed in other animals,” the agency said in an email.

In company trials, both men and women were instructed to either use contraception or abstain from sex. Pregnant women were excluded from the study. Merck has stated that the drug is safe when used as directed.

Molnupiravir was initially studied as a potential flu therapy with funding from the U.S. government. Last year, researchers at Emory University decided to repurpose the drug as a potential COVID-19 treatment. They then licensed the drug to Ridgeback and partner Merck.

Last week, Merck agreed to allow other drugmakers to make its COVID-19 pill, in a move aimed at helping millions of people in poorer countries get access. The Medicines Patent Pool, a U.N.-backed group, said Merck will not receive royalties under the agreement for as long as the World Health Organization deems COVID-19 to be a global emergency.

But the deal was criticized by some activists for excluding many middle-income countries capable of making millions of treatments, including Brazil and China.

Still, experts commended Merck for agreeing to widely share its formula and promising to help any companies who need technological help in making their drug — something no coronavirus vaccine producers have agreed to.

“Unlike the grotesquely unequal distribution of COVID-19 vaccines, the poorest countries will not have to wait at the back of the queue for molnupiravir,” said Dr. Mohga Kamal-Yanni, a senior health adviser to the People’s Vaccine Alliance. Fewer than 1% of the world’s COVID-19 vaccines have gone to poor countries and experts hope easier-to-dispense treatments will help them curb the pandemic.

Merck previously announced licensing deals with several Indian makers of generic drugs to manufacture lower-cost versions of molnupiravir for developing countries.

The U.S. has agreed to pay roughly $700 per course of the drug for about 1.7 million treatments. Merck says it plans to use a tiered pricing strategy for developing countries. A review by Harvard University and King’s College London estimated the drug costs about $18 to make each 40-pill course of treatment.

While other treatments have been cleared to treat COVID-19, including steroids and monoclonal antibodies, those are administered by injection or infusion and are mostly used in hospitals and other health care facilities.

___

Matthew Perrone reported from Washington.

___

Follow AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic

___

This story has been corrected to show that Merck announced preliminary results in September, not last month.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

AP

From left, Czech Republic's Prime Minister Petr Fiala, Azerbaijan's President Ilham Aliyev and Turk...
Associated Press

Leaders of Turkey, Armenia, hold face-to-face meeting

PRAGUE (AP) — The leaders of historic foes Turkey and Armenia on Thursday held their first face-to-face meeting since the two countries agreed to improve relations. Turkish President Recep Tayyip Erdogan and Prime Minister Nikol Pashinyan met in Prague on the sidelines of a summit by the leaders of 44 countries to launch a “European […]
1 day ago
International Monetary Fund Managing Director Kristalina Georgieva speaks on the global economic ou...
Associated Press

IMF warns of higher recession risk and darker global outlook

WASHINGTON (AP) — The International Monetary Fund is once again lowering its projections for global economic growth in 2023, projecting world economic growth lower by $4 trillion through 2026. Kristalina Georgieva, managing director of the IMF, told an audience at Georgetown University on Thursday that “things are more likely to get worse before it gets […]
1 day ago
Associated Press

JetBlue bid for Spirit wins support from 2 advisory firms

JetBlue’s $3.8 billion bid to buy Spirit Airlines has been endorsed by two firms that advise major investors on how to vote. Institutional Shareholder Services and Glass, Lewis & Co. recommended that Spirit stockholders vote to accept JetBlue’s offer when they vote on Oct. 19. Spirit CEO Ted Christie said Thursday that the companies are […]
1 day ago
Eric Santos uses a suitcase that he keeps all of his possessions in as a table while having a cup o...
Associated Press

Amid end to COVID help, homelessness surging in many cities

SACRAMENTO, Calif. (AP) — In California’s capital, massive tent encampments have risen along the American River and highway overpasses have become havens for homeless people, whose numbers have jumped a staggering nearly 70% over two years. Among the 9,300 without a home is Eric Santos, who lost his job at a brewery and was evicted […]
1 day ago
Lewis Lopez places his hand on his Bible, Tuesday, Aug. 30, 2022, in his apartment in the Dorcheste...
Associated Press

Amid end to COVID help, homelessness surging in many cities

SACRAMENTO, Calif. (AP) — In California’s capital, massive tent encampments have risen along the American River and highway overpasses have become havens for homeless people, whose numbers have jumped a staggering nearly 70% over two years. Among the 9,300 without a home is Eric Santos, who lost his job at a brewery and was evicted […]
1 day ago
FILE - Nobel Peace Prize winners Dmitry Muratov from Russia, right, and Maria Ressa of the Philippi...
Associated Press

2021 Nobel Peace Prize winners have faced a year of battles

WASHINGTON (AP) — Winning the Nobel Peace Prize often provides a boost for a grassroots activist or international group working for peace and human rights, opening doors and elevating the causes for which they fight. But it doesn’t always work out that way. For the two journalists who won the Nobel Peace Prize in 2021, […]
1 day ago

Sponsored Articles

Anacortes Christmas Tree...

Come one, come all! Food, Drink, and Coastal Christmas – Anacortes has it all!

Come celebrate Anacortes’ 11th annual Bier on the Pier! Bier on the Pier takes place on October 7th and 8th and features local ciders, food trucks and live music - not to mention the beautiful views of the Guemes Channel and backdrop of downtown Anacortes.
Swedish Cyberknife Treatment...

The revolutionary treatment of Swedish CyberKnife provides better quality of life for majority of patients

There are a wide variety of treatments options available for men with prostate cancer. One of the most technologically advanced treatment options in the Pacific Northwest is Stereotactic Body Radiation Therapy using the CyberKnife platform at Swedish Medical Center.
Work at Zum Services...

Seattle Public Schools announces three-year contract with Zum

Seattle Public Schools just announced a three-year contract with a brand-new company to the Pacific Northwest to assist with their student transportation: Zum.
Swedish Cyberknife 900x506...

June is Men’s Health Month: Here’s Why It’s Important To Speak About Your Health

According to the Centers for Disease Control and Prevention, men in the United States, on average, die five years earlier than women.
...

Anacortes – A Must Visit Summertime Destination

While Anacortes is certainly on the way to the San Juan Islands (SJI), it is not just a destination to get to the ferry… Anacortes is a destination in and of itself!
...

Ready for your 2022 Alaskan Adventure with Celebrity Cruises?

Celebrity Cruises SPONSORED — A round-trip Alaska cruise from Seattle is an amazing treat for you and a loved one. Not only are you able to see and explore some of the most incredible and visually appealing natural sights on the planet, but you’re also able to relax and re-energize while aboard a luxury cruise […]
UK authorizes Merck antiviral pill, 1st shown to treat COVID